Abstract

Chemokine receptors (CKRs) are G protein coupled receptors (GPCRs), a super-family of transmembrane receptors that are the target of ∼1/3 of FDA-approved medications. CKRs are critical regulators of the immune response, in part through their central role in chemotaxis, and therefore play a role in nearly every inflammatory skin condition. Despite their critical role in regulating inflammation, few FDA-approved medications target CKRs. The purpose of this study was to identify CKR signaling pathways that could provide new opportunities for drug development.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call